laboratori corpor america hold lh
laboratori corp america
covanc growth keep lh buy
would character lh result larg in-lin modest revenue miss
covanc modest earn beat cost initi maintain posit view
stock given belief real opportun invest stori name
emerg pln opportun underappreci investor
key perform driver begin next year covanc see continu
slight miss top-lin ebitda ep beat revenu ep
covanc revenu growth miss street estim slightli vs
lab revenu in-lin lh beat ebitda vs
ep vs primarili launchpad save guidanc front
lh narrow top-lin rang ep
organ covanc growth launchpad save help off-set multitud previous
known lab headwind expect volum headwind result lose
in-network exclus horizon bcbs-nj continu pama reimburs
cut declin consum genet test market neg
impact top bottom line lh expect headwind
persist believ save lh launchpad initi combin
covanc solid organ revenu growth outlook margin expans
suffici drive ebitda growth
lh invest stori realli begin pln opportun emerg
report suggest lh inclus one five player prefer lab
network pln emerg signific revenue earn driver beyond
ramp adopt take year reach full potenti
nt opportun lh quickli gain market share counti
domin presenc optumcar physician group
larg popul member area easi opportun
provid member physician incent drive market share pln member
pln effect bring cost gain traction show
track record save expect interest narrow network lab strategi emerg
among employ health benefit sponsor provid runway pln
tailwind
result multipl expans recogn ebitda growth like
mute believ lh multipl expand investor take account
emerg multi-year pln growth opportun start addit
continu strong covanc organ revenu growth margin expans
ep amort non-recur item
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
laboratori corpor america hold lh
rais pt deriv appli discount vs price-to-earnings
ep estim
pleas see import disclosur inform page report
laboratori corpor america hold lh
ep amort non-recur item
lab segment pama-rel reimburs cut
like limit ebitda growth upsid even w/
organ volum growth
cro segment revenu op incom
growth acceler chiltern acquisit
integr launchpad gener increment cost
lh like need reli strateg lab
segment order grow ebitda meaning
synergi lab cro segment could
drive acceler growth new order revenu
op incom cro segment
save project launchpad could allow margin
cro segment expand meaning
lh abl off-set volum loss inclus
network via better anticip share
shift within aet book busi
lab segment continu slowdown us
healthcar util environ loss
volum via dgx inclus within contract
caus volum weak
pama-rel medicar reimburs cut
anticip
cro segment integr risk covanc
chiltern could caus synergi fall
buy rate lh given belief
announc prefer lab network posit
catalyst stock inclus like bolster
organ growth begin
covanc gain market share driven data-
driven approach integr compani
core labcorp busi
pleas see import disclosur inform page report
laboratori corpor america hold lh
pleas see import disclosur inform page report
 dollar million unless otherwis indic year end growth growth gross expens method incom expens pre-tax net incom lh averag dilut growth dilut ep growth growth size statementnet gross expens method incom expens pre-tax net incom lh exhibit lh balanc sheet
laboratori corpor america hold lh
pleas see import disclosur inform page report
 dollar million unless otherwis indic -fiscal year end cash receiv current total current asset partnerships/equ asset total portion long-term oper financ leas expens total current oper financ leas incom total liab dollar million unless otherwis indic year end non-cash work flow oper invest flow invest issuanc issuanc financ flow financ exchang rate increas decreas ratiosstock compens expenditur a- -- -- -- -- -- -- -- -- -- -- -acquisit pp -- -- -- -- -- -- -- -- -- -- -free equiti research
laboratori corpor america hold lh
laboratori corp america
laboratori corpor america hold lead healthcar diagnost compani provid comprehens clinic laboratori
servic labcorp diagnost end-to-end drug develop support covanc drug develop
laboratori corp america
pt deriv appli discount vs price-to-earnings ep estim risk volum shift
expect marketshar gain independ region lab less expect
brian tanquilut certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
bryan ross cfa certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
jason plagman certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
pleas see import disclosur inform page report
